Details for Patent: 8,071,644

Which drugs does patent 8,071,644 protect, and when does it expire?

Patent 8,071,644 protects EPIDUO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 8,071,644

Title:	Combinations of adapalene and benzoyl peroxide for treating acne lesions
Abstract:	Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
Inventor(s):	Abou-Chacra Vernet; Marie-line (Nice, FR), Gross; Denis (Callian, FR), Loesche; Christian (Valbonne, FR), Poncet; Michel (Mougins, FR)
Assignee:	Galderma Research & Development (Biot, FR)
Application Number:	12/318,937
Patent Claim Types: see list of patent claims	Use; Compound;

Drugs Protected by US Patent 8,071,644

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes			Y			TREATMENT OF ACNE

Foreign Priority and PCT Information for Patent: 8,071,644

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	06 52968	Jul 13, 2006

International Family Members for US Patent 8,071,644

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061989
Australia	2007274288
Brazil	PI0713182
Canada	2656456